| Julie A Brody, OT | |
|
6273 Franconia Rd, Alexandria, VA 22310-2510 | |
| (703) 719-9460 | |
| (703) 719-9461 |
| Full Name | Julie A Brody |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Hand |
| Location | 6273 Franconia Rd, Alexandria, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174509830 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XH1200X | Occupational Therapist - Hand | 0119001308 (Virginia) | Primary |
| Provider Name | Nirschl Orthopaedic Center For Sportsmedicine & Joint Reconstruction |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1053459149 PECOS PAC ID: 8729065420 Enrollment ID: O20040701000074 |
News Archive
DSM, a global leader in biomedical materials sciences, today announced that it is contributing proprietary knowledge in the preparation of tailored amino acid-based polymers and offering use of processing facilities that will produce an innovative step change in the sustained delivery of drug molecules. The PANOPTES consortium's goal is to research and develop novel drug delivery technology for the posterior eye segment. This partnership further validates the innovative properties of DSM's polyesteramide (PEA) biomaterials as a superior drug delivery technology.
Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.
Boehringer Ingelheim announced today that the European Commission has approved an update to the Summary of Product Characteristics (SmPC) for VIRAMUNE (nevirapine) in the treatment of patients with HIV.
Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie A Brody, OT 11240 Waples Mill Rd, Suite 202, Fairfax, VA 22030-6078 Ph: (703) 255-2339 | Julie A Brody, OT 6273 Franconia Rd, Alexandria, VA 22310-2510 Ph: (703) 719-9460 |
News Archive
DSM, a global leader in biomedical materials sciences, today announced that it is contributing proprietary knowledge in the preparation of tailored amino acid-based polymers and offering use of processing facilities that will produce an innovative step change in the sustained delivery of drug molecules. The PANOPTES consortium's goal is to research and develop novel drug delivery technology for the posterior eye segment. This partnership further validates the innovative properties of DSM's polyesteramide (PEA) biomaterials as a superior drug delivery technology.
Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.
Boehringer Ingelheim announced today that the European Commission has approved an update to the Summary of Product Characteristics (SmPC) for VIRAMUNE (nevirapine) in the treatment of patients with HIV.
Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.
› Verified 8 days ago
Ms. Vera Jackson Giles, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5705 Shropshire Ct, Alexandria, VA 22315 Phone: 703-626-1120 Fax: 703-921-2193 | |
John Adkins, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 4835 W Braddock Rd Apt 3, Alexandria, VA 22311 Phone: 304-417-1221 | |
Ms. Alexandra V Lozada-pelczynski, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 6019 Archstone Way, Alexandria, VA 22310 Phone: 516-732-2062 | |
Emily Shea, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8111 Tis Well Dr, Alexandria, VA 22306 Phone: 703-348-7571 | |
Annissia Hawkins, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4605g Pinecrest Office Park Dr, Alexandria, VA 22312 Phone: 703-813-6330 Fax: 301-710-6379 | |
Ms. Kathy M Caplins, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7117 Strawn Ct, Alexandria, VA 22306 Phone: 703-209-5155 | |
Holistic Advantage Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 205 S Whiting St Ste 200, Alexandria, VA 22304 Phone: 781-654-5267 |